Skip to main content
padlock icon - secure page this page is secure

Increased serum levels of matrix metalloproteinase-9 predict clinical outcome of patients with early B-cell chronic lymphocytic leukaemia

Buy Article:

$59.00 + tax (Refund Policy)

Molica S, Vitelli G, Levato D, Giannarelli D, Vacca A, Cuneo A, Cavazzini F, Squillace R, Mirabelli R, Digiesi D. Increased serum levels of matrix metalloproteinase-9 predict clinical outcome of patients with early B-cell chronic lymphocytic leukaemia.

Eur J Haematol 2003: 70: 373–378. © Blackwell Munksgaard 2003. Abstract: Background and Methods:

Serum levels of matrix metalloproteinase-9 (MMP-9) which agree with progression in solid and haematological tumours were correlated to the risk of disease progression in 62 patients with early (Binet stage A) B-cell chronic lymphocytic leukaemia (CLL). Sera were taken at diagnosis and tested by an enzyme-linked immunosorbent assay. Results:

MMP-9 levels positively correlated with haemoglobin levels (P = 0.03) and platelet count (P = 0.03). No association was found with main clinico-haematological features representative of tumour mass, such as peripheral blood lymphocytosis, bone marrow histology, Rai substages and -2 microglobulin (-2m). A cut-off of MMP-9 levels corresponding to 33rd percentile (203 ng/mL) or higher identified earlier upstaging and shorter progression-free survival. MMP-9 was a significant prognostic marker in multivariate analysis and partially independent of Rai substages, which suggests its inclusion into such a staging system to better stratify prognostically Rai stages I and II patients. Conclusions:

MMP-9 serum levels predict disease behaviour and help to refine the prognosis of stage A CLL patients.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: disease progression; matrix metalloproteinase-9; stage A chronic lymphocytic leukaemia

Document Type: Research Article

Affiliations: 1: Medical Oncology Unit, Azienda Ospedaliera ‘Pugliese-Ciaccio’, Catanzaro; 2: Clinical Pathology Service, Istituto ‘Regina Elena’ IRCCS, Rome; 3: Department of Biomedical Sciences and Human Oncology, Bari and 4: Institute of Hematology, University of Ferrara, Ferrara, Italy

Publication date: June 1, 2003

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more